L’essentiel de l’actualité en cardio-oncologie
Chaque semaine, retrouvez l’actualité en cardio-oncologie, sélectionnée par le Groupe de Cardio-Oncologie (GCO).
Mars
- Effectiveness and Safety of Rivaroxaban and Low Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism >> SCIENCE DIRECT
- Genetic Predisposition to Cardiovascular Disease in Patients With Cancer: A Clinical Perspective >> SCIENCE DIRECT
Février
- Radiation-Induced Aortic Stenosis: An Update on Treatment Modalities >> JACC
- Heart Valve Team Conundrum: The Optimal Management Strategy of Severe Aortic Stenosis in Cancer Patients >> JACC
- Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial >> JAMA NETWORK
- Coronary Artery Calcium for Cardiovascular Risk Estimation in Patients With Cancer >> AHA JOURNALS
- Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study >> AHA JOURNALS
- Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review >> JACC
- Association of Midlife Cardiovascular Health and Subsequent Change in Cardiovascular Health With Incident Cancer >> JACC
- The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer: A RADICAL-PC Analysis >> JACC
- Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer >> JACC
- Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up >> JACC
- Impact of Age at Diagnosis on Cardiotoxicity in High-Grade Osteosarcoma and Ewing Sarcoma Patients >> JACC
- The European Society of Cardiology Cardio-Oncology Guidelines: Evidence Base, Actionability, and Relevance to Clinical Practice >> JACC
Janvier
- Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation >> JACC
- The European Society of Cardiology Cardio-Oncology Guidelines: Evidence Base, Actionability, and Relevance to Clinical Practice >> JACC
- Improvements in Efficacy Measures With Tafamidis in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial >> JACC
- Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer >> JAMA NETWORK
- Cardiovascular outcomes in patients with cancer during a 5-year follow-up: Results from a French administrative database >> SCIENCE DIRECT